Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease

Sci Rep. 2021 May 27;11(1):11086. doi: 10.1038/s41598-021-90441-x.


Leucine-rich alpha-2 glycoprotein (LRG) may be a novel serum biomarker for patients with inflammatory bowel disease. The association of LRG with the endoscopic activity and predictability of mucosal healing (MH) was determined and compared with those of C-reactive protein (CRP) and fecal markers (fecal immunochemical test [FIT] and fecal calprotectin [Fcal]) in 166 ulcerative colitis (UC) and 56 Crohn's disease (CD) patients. In UC, LRG was correlated with the endoscopic activity and could predict MH, but the performance was not superior to that of fecal markers (areas under the curve [AUCs] for predicting MH: LRG: 0.61, CRP: 0.59, FIT: 0.75, and Fcal: 0.72). In CD, the performance of LRG was equivalent to that of CRP and Fcal (AUCs for predicting MH: LRG: 0.82, CRP: 0.82, FIT: 0.70, and Fcal: 0.88). LRG was able to discriminate patients with MH from those with endoscopic activity among UC and CD patients with normal CRP levels. LRG was associated with endoscopic activity and could predict MH in both UC and CD patients. It may be particularly useful in CD.

MeSH terms

  • Adolescent
  • Adult
  • C-Reactive Protein / metabolism
  • Colonoscopy
  • Female
  • Glycoproteins / blood*
  • Humans
  • Inflammatory Bowel Diseases / blood*
  • Inflammatory Bowel Diseases / pathology
  • Intestinal Mucosa / pathology*
  • Male
  • Wound Healing / physiology
  • Young Adult


  • Glycoproteins
  • LRG1 protein, human
  • C-Reactive Protein